Previous Close | 97.97 |
Open | 98.79 |
Bid | 97.20 x N/A |
Ask | 97.82 x N/A |
Day's Range | 98.79 - 98.79 |
52 Week Range | 85.60 - 173.78 |
Volume | |
Avg. Volume | 7 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Investing.com -- Gene-sequencing firm Illumina (NASDAQ:ILMN) said it would take goodwill impairment charge of $1.47 billion in its second quarter linked to its recently spun-off cancer diagnostic test manufacturer Grail (NASDAQ:GRAL).
Gene-sequencing equipment maker Illumina said it will likely recognize an additional impairment charge of about $420 million for Grail's in-process research and development intangible (IPR&D) asset in the quarter ended June. In December, activist investor Carl Icahn said Grail's greater-than-expected expenditure and delays in advancing its tests had also forced Illumina to take impairments that totaled $4.7 billion.
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.